^
    Back
    Association details:
    Biomarker:MGMT unmethylation
    Cancer:Glioma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    ProstAtak (aglatimagene besadenovec) (Gene transference, Thymidine kinase stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2022
    Title:

    1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma

    Published date:
    11/08/2022
    Excerpt:
    mOS for patients with unmethylated MGMT was 13.2mo (GTR) and 15.9mo (STR)….Combination treatment of CAN-2409/valacyclovir plus nivolumab and SoC induces profound immunological changes and appears to associate with encouraging survival data.
    Secondary therapy:
    valacyclovir
    DOI:
    http://dx.doi.org/10.1136/jitc-2022-SITC2022.1477
    Trial ID:
    GMCI